Suppr超能文献

[对乙酰氨基酚固体和液体制剂及直肠剂型给药后的相对生物利用度]

[The relative bioavailability of paracetamol following administration of solid and liquid oral preparations and rectal dosage forms].

作者信息

Walter-Sack I, Luckow V, Guserle R, Weber E

机构信息

Abteilung Klinische Pharmakologie, Medizinische Klinik der Universität Heidelberg.

出版信息

Arzneimittelforschung. 1989 Jun;39(6):719-24.

PMID:2775340
Abstract

Determination of the Relative Bioavailability of Paracetamol Following Administration of Solid and Liquid Oral Preparations and Rectal Dosage Forms. The relative bioavailability of paracetamol from two solid and two liquid oral preparations and two rectal dosage forms, each containing 500 mg of the active ingredient, was investigated in 12 healthy male individuals. The plasma concentration-time curves of paracetamol following administration of the oral formulations were very similar; consequently there were only minor differences of the AUC0-12h (21.4, 21.9; 23.0, 22.8 micrograms.h/ml), cmax (8.8, 9.1; 10.0, 10.7 micrograms/ml), tmax (35, 25; 20, 19 min), and the terminal plasma elimination half-life t1/2 beta (2.95, 2.85; 2.86, 2.99 h) for the solid and the liquid test and reference preparations, respectively. The suppositories (test and reference formulation) differed from the oral dosage forms, but were comparable to each other with respect to AUC0-12h (18.2, 18.8 micrograms.h/ml), cmax (3.3, 3.5 micrograms/ml), tmax (1.6, 2.45 h), and t1/2 beta (3.55, 3.54 h). In all test preparations the 95% confidence limits for AUC0-12h completely were enclosed in the range of 80-120% relative bioavailability (independently of whether parametric or non-parametric statistical methods were applied); the limits for the oral formulations were quite narrow, thus indicating a highly consistent release of the active compound from the tablets as well as from the liquid dosage form. A comparison of the mean values of cmax by analysis of variance at the 80% probability level did not reveal any significant differences between the test and the corresponding reference formulations; based on non-parametric statistical methods, the 95% confidence limits for cmax were enclosed in the range of 70-130%.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

对乙酰氨基酚固体和液体口服制剂及直肠剂型给药后的相对生物利用度测定。在12名健康男性个体中,研究了两种固体和两种液体口服制剂以及两种直肠剂型中对乙酰氨基酚的相对生物利用度,每种制剂均含有500mg活性成分。口服制剂给药后对乙酰氨基酚的血浆浓度 - 时间曲线非常相似;因此,固体和液体试验制剂与参比制剂的AUC0 - 12h(21.4、21.9;23.0、22.8μg·h/ml)、cmax(8.8、9.1;10.0、10.7μg/ml)、tmax(35、25;20、19分钟)以及血浆消除终末半衰期t1/2β(2.95、2.85;2.86、2.99小时)仅存在微小差异。栓剂(试验制剂和参比制剂)与口服剂型不同,但在AUC0 - 12h(18.2、18.8μg·h/ml)、cmax(3.3、3.5μg/ml)、tmax(1.6、2.45小时)和t1/2β(3.55、3.54小时)方面彼此相当。在所有试验制剂中,AUC0 - 12h的95%置信限完全在相对生物利用度80 - 120%的范围内(无论应用参数统计方法还是非参数统计方法);口服制剂的置信限很窄,表明活性化合物从片剂以及液体制剂中的释放高度一致。在80%概率水平下通过方差分析比较cmax的平均值,未发现试验制剂与相应参比制剂之间存在任何显著差异;基于非参数统计方法,cmax的95%置信限在70 - 130%的范围内。(摘要截短于250字)

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验